Renal effects of levosimendan

A consensus report

Mehmet B. Yilmaz, Elena Grossini, José C. Silva Cardoso, I. Édes, Francesco Fedele, Piero Pollesello, Matti Kivikko, Veli Pekka Harjola, Julia Hasslacher, Alexandre Mebazaa, Andrea Morelli, Jos Le Noble, Anders Oldner, Ignacio Oulego Erroz, John T. Parissis, Alexander Parkhomenko, Gerhard Poelzl, Sebastian Rehberg, Sven Erik Ricksten, Luís M. Rodríguez Fernández & 5 others Markku Salmenperä, Mervyn Singer, Sascha Treskatsch, Bojan Vrtovec, Gerhard Wikström

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards themechanism of action, the opening of mitochondrial KATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).

Original languageEnglish
Pages (from-to)581-590
Number of pages10
JournalCardiovascular Drugs and Therapy
Volume27
Issue number6
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Kidney
Thoracic Surgery
Sepsis
Heart Failure
Slovenia
Ukraine
Portugal
Hungary
Austria
Potassium Channels
Greece
Calcium Channels
Finland
Turkey
simendan
Sweden
Netherlands
Spain
Italy
France

Keywords

  • Levosimendan
  • Renal dysfunction

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Yilmaz, M. B., Grossini, E., Silva Cardoso, J. C., Édes, I., Fedele, F., Pollesello, P., ... Wikström, G. (2013). Renal effects of levosimendan: A consensus report. Cardiovascular Drugs and Therapy, 27(6), 581-590. https://doi.org/10.1007/s10557-013-6485-6

Renal effects of levosimendan : A consensus report. / Yilmaz, Mehmet B.; Grossini, Elena; Silva Cardoso, José C.; Édes, I.; Fedele, Francesco; Pollesello, Piero; Kivikko, Matti; Harjola, Veli Pekka; Hasslacher, Julia; Mebazaa, Alexandre; Morelli, Andrea; Le Noble, Jos; Oldner, Anders; Erroz, Ignacio Oulego; Parissis, John T.; Parkhomenko, Alexander; Poelzl, Gerhard; Rehberg, Sebastian; Ricksten, Sven Erik; Rodríguez Fernández, Luís M.; Salmenperä, Markku; Singer, Mervyn; Treskatsch, Sascha; Vrtovec, Bojan; Wikström, Gerhard.

In: Cardiovascular Drugs and Therapy, Vol. 27, No. 6, 12.2013, p. 581-590.

Research output: Contribution to journalArticle

Yilmaz, MB, Grossini, E, Silva Cardoso, JC, Édes, I, Fedele, F, Pollesello, P, Kivikko, M, Harjola, VP, Hasslacher, J, Mebazaa, A, Morelli, A, Le Noble, J, Oldner, A, Erroz, IO, Parissis, JT, Parkhomenko, A, Poelzl, G, Rehberg, S, Ricksten, SE, Rodríguez Fernández, LM, Salmenperä, M, Singer, M, Treskatsch, S, Vrtovec, B & Wikström, G 2013, 'Renal effects of levosimendan: A consensus report', Cardiovascular Drugs and Therapy, vol. 27, no. 6, pp. 581-590. https://doi.org/10.1007/s10557-013-6485-6
Yilmaz MB, Grossini E, Silva Cardoso JC, Édes I, Fedele F, Pollesello P et al. Renal effects of levosimendan: A consensus report. Cardiovascular Drugs and Therapy. 2013 Dec;27(6):581-590. https://doi.org/10.1007/s10557-013-6485-6
Yilmaz, Mehmet B. ; Grossini, Elena ; Silva Cardoso, José C. ; Édes, I. ; Fedele, Francesco ; Pollesello, Piero ; Kivikko, Matti ; Harjola, Veli Pekka ; Hasslacher, Julia ; Mebazaa, Alexandre ; Morelli, Andrea ; Le Noble, Jos ; Oldner, Anders ; Erroz, Ignacio Oulego ; Parissis, John T. ; Parkhomenko, Alexander ; Poelzl, Gerhard ; Rehberg, Sebastian ; Ricksten, Sven Erik ; Rodríguez Fernández, Luís M. ; Salmenperä, Markku ; Singer, Mervyn ; Treskatsch, Sascha ; Vrtovec, Bojan ; Wikström, Gerhard. / Renal effects of levosimendan : A consensus report. In: Cardiovascular Drugs and Therapy. 2013 ; Vol. 27, No. 6. pp. 581-590.
@article{d7be845977db4d2b9d6d9d7bbccd2f34,
title = "Renal effects of levosimendan: A consensus report",
abstract = "Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards themechanism of action, the opening of mitochondrial KATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).",
keywords = "Levosimendan, Renal dysfunction",
author = "Yilmaz, {Mehmet B.} and Elena Grossini and {Silva Cardoso}, {Jos{\'e} C.} and I. {\'E}des and Francesco Fedele and Piero Pollesello and Matti Kivikko and Harjola, {Veli Pekka} and Julia Hasslacher and Alexandre Mebazaa and Andrea Morelli and {Le Noble}, Jos and Anders Oldner and Erroz, {Ignacio Oulego} and Parissis, {John T.} and Alexander Parkhomenko and Gerhard Poelzl and Sebastian Rehberg and Ricksten, {Sven Erik} and {Rodr{\'i}guez Fern{\'a}ndez}, {Lu{\'i}s M.} and Markku Salmenper{\"a} and Mervyn Singer and Sascha Treskatsch and Bojan Vrtovec and Gerhard Wikstr{\"o}m",
year = "2013",
month = "12",
doi = "10.1007/s10557-013-6485-6",
language = "English",
volume = "27",
pages = "581--590",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "6",

}

TY - JOUR

T1 - Renal effects of levosimendan

T2 - A consensus report

AU - Yilmaz, Mehmet B.

AU - Grossini, Elena

AU - Silva Cardoso, José C.

AU - Édes, I.

AU - Fedele, Francesco

AU - Pollesello, Piero

AU - Kivikko, Matti

AU - Harjola, Veli Pekka

AU - Hasslacher, Julia

AU - Mebazaa, Alexandre

AU - Morelli, Andrea

AU - Le Noble, Jos

AU - Oldner, Anders

AU - Erroz, Ignacio Oulego

AU - Parissis, John T.

AU - Parkhomenko, Alexander

AU - Poelzl, Gerhard

AU - Rehberg, Sebastian

AU - Ricksten, Sven Erik

AU - Rodríguez Fernández, Luís M.

AU - Salmenperä, Markku

AU - Singer, Mervyn

AU - Treskatsch, Sascha

AU - Vrtovec, Bojan

AU - Wikström, Gerhard

PY - 2013/12

Y1 - 2013/12

N2 - Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards themechanism of action, the opening of mitochondrial KATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).

AB - Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards themechanism of action, the opening of mitochondrial KATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).

KW - Levosimendan

KW - Renal dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84892373432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892373432&partnerID=8YFLogxK

U2 - 10.1007/s10557-013-6485-6

DO - 10.1007/s10557-013-6485-6

M3 - Article

VL - 27

SP - 581

EP - 590

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 6

ER -